Stock Track | Monte Rosa Therapeutics Soars 50.91% in Pre-market on Positive Phase 1 Trial Results for MRT-8102

Stock Track

Jan 07

Monte Rosa Therapeutics (GLUE) saw its stock surge 50.91% in pre-market trading on Wednesday following the announcement of positive interim Phase 1 clinical trial results for its experimental drug MRT-8102.

The drug, targeting NEK7 for inflammatory diseases, demonstrated an 85% reduction in C-reactive protein (CRP) levels in patients with elevated cardiovascular disease (CVD) risk. Additionally, 94% of participants achieved CRP levels below 2 mg/L, a threshold associated with reduced CVD risk. The trial also reported a favorable safety profile with mild to moderate adverse events.

Monte Rosa plans to initiate a Phase 2 study for MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) in 2026, with further evaluations in metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1115572136"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1115572136\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1115572136?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-07 20:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1115572136","market":"us","top_or_hot":-1,"title":"Stock Track | Monte Rosa Therapeutics Soars 50.91% in Pre-market on Positive Phase 1 Trial Results for MRT-8102","media":"Stock Track","content":"<p>Monte Rosa Therapeutics (GLUE) saw its stock surge 50.91% in pre-market trading on Wednesday following the announcement of positive interim Phase 1 clinical trial results for its experimental drug MRT-8102.</p><p>The drug, targeting NEK7 for inflammatory diseases, demonstrated an 85% reduction in C-reactive protein (CRP) levels in patients with elevated cardiovascular disease (CVD) risk. Additionally, 94% of participants achieved CRP levels below 2 mg/L, a threshold associated with reduced CVD risk. The trial also reported a favorable safety profile with mild to moderate adverse events.</p><p>Monte Rosa plans to initiate a Phase 2 study for MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) in 2026, with further evaluations in metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Monte Rosa Therapeutics Soars 50.91% in Pre-market on Positive Phase 1 Trial Results for MRT-8102</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Monte Rosa Therapeutics Soars 50.91% in Pre-market on Positive Phase 1 Trial Results for MRT-8102\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-01-07 20:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Monte Rosa Therapeutics (GLUE) saw its stock surge 50.91% in pre-market trading on Wednesday following the announcement of positive interim Phase 1 clinical trial results for its experimental drug MRT-8102.</p><p>The drug, targeting NEK7 for inflammatory diseases, demonstrated an 85% reduction in C-reactive protein (CRP) levels in patients with elevated cardiovascular disease (CVD) risk. Additionally, 94% of participants achieved CRP levels below 2 mg/L, a threshold associated with reduced CVD risk. The trial also reported a favorable safety profile with mild to moderate adverse events.</p><p>Monte Rosa plans to initiate a Phase 2 study for MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) in 2026, with further evaluations in metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GLUE","symbol_name":"Monte Rosa Therapeutics","start_time":0,"source_url":"","article_id":"1115572136","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1115572136","pubTimestamp":1767790583,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Monte Rosa Therapeutics (GLUE) saw its stock surge 50.91% in pre-market trading on Wednesday following the announcement of positive interim Phase 1 clinical trial results for its experimental drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GLUE":"Monte Rosa Therapeutics"},"translate_title":"个股追踪|Monte Rosa Therapeutics盘前飙升50.91%，因MRT-8102 1期试验结果积极","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GLUE":1},"content_text":"Monte Rosa Therapeutics (GLUE) saw its stock surge 50.91% in pre-market trading on Wednesday following the announcement of positive interim Phase 1 clinical trial results for its experimental drug MRT-8102.The drug, targeting NEK7 for inflammatory diseases, demonstrated an 85% reduction in C-reactive protein (CRP) levels in patients with elevated cardiovascular disease (CVD) risk. Additionally, 94% of participants achieved CRP levels below 2 mg/L, a threshold associated with reduced CVD risk. The trial also reported a favorable safety profile with mild to moderate adverse events.Monte Rosa plans to initiate a Phase 2 study for MRT-8102 in atherosclerotic cardiovascular disease (ASCVD) in 2026, with further evaluations in metabolic dysfunction-associated steatohepatitis (MASH), gout, and recurrent pericarditis.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}